Literature DB >> 11068913

Discriminatory detection of extended-spectrum beta-lactamases by restriction fragment length dimorphism-polymerase chain reaction.

S H Lee1, J Y Kim, S K Lee, W Jin, S G Kang, K J Lee.   

Abstract

Plasmid-mediated resistance mechanisms to beta-lactams, comprising mostly extended-spectrum beta-lactamase (ESBL) production, lead to resistance against even the most recently developed beta-lactams in enterobacteria, which is now a serious threat to antibiotic therapy. In this work, the diagnostic ability of the restriction fragment length dimorphism (RFLD)-polymerase chain reaction (PCR) method in clinical samples was evaluated. Nine newly designed primer pairs were used to differentiate the genes encoding TEM-1a, SHV-12, MOX-1, MIR-1 and Toho-1 beta-lactamases. The RFLD-PCR was carried out successfully and these genes were differentiated by the sizes of their PCR product. This discriminatory detection of the genes was also confirmed by digestion with unique restriction enzyme sites and sequencing of the PCR products. The fragment sizes of PCR products digested with the enzymes were identical to the sizes calculated from nucleotide sequences of five beta-lactamase genes deposited in EMBL, GenBank and/or DDBJ databases and the sequences were also identical. In conclusion, the method and newly designed primers applied in this work can differentiate the ESBLs rapidly and effectively.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11068913     DOI: 10.1046/j.1472-765x.2000.00806.x

Source DB:  PubMed          Journal:  Lett Appl Microbiol        ISSN: 0266-8254            Impact factor:   2.858


  5 in total

1.  Detection and genotyping of SHV beta-lactamase variants by mass spectrometry after base-specific cleavage of in vitro-generated RNA transcripts.

Authors:  Enno Stürenburg; Niels Storm; Ingo Sobottka; Matthias A Horstkotte; Stefanie Scherpe; Martin Aepfelbacher; Susanne Müller
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

2.  Comparison of Commensal and Clinical Isolates for Diversity of Plasmids in Escherichia coli and Klebsiella pneumoniae.

Authors:  Paula Espinal; Ferran Navarro; Judith Rodríguez-Navarro; Elisenda Miró; Maryury Brown-Jaque; Juan Carlos Hurtado; Albert Moreno; Maite Muniesa; Juan José González-López; Jordi Vila
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

3.  Molecular characterization of extended-spectrum beta-lactamases produced by clinical isolates of Klebsiella pneumoniae and Escherichia coli from a Korean nationwide survey.

Authors:  Seok Hoon Jeong; Il Kwon Bae; Jung Hun Lee; Seung Ghyu Sohn; Geun Ho Kang; Ghil Ja Jeon; Young Ho Kim; Byeong Chul Jeong; Sang Hee Lee
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

4.  Ertapenem resistance among extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolates.

Authors:  Azita Leavitt; Inna Chmelnitsky; Raul Colodner; Itzhak Ofek; Yehuda Carmeli; Shiri Navon-Venezia
Journal:  J Clin Microbiol       Date:  2009-02-11       Impact factor: 5.948

5.  Clinical outcome of Escherichia coli bloodstream infection in cancer patients with/without biofilm formation: a single-center retrospective study.

Authors:  Qing Zhang; Hao-Yang Gao; Ding Li; Zheng Li; Shan-Shan Qi; Shan Zheng; Chang-Sen Bai; Si-He Zhang
Journal:  Infect Drug Resist       Date:  2019-02-11       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.